Generated by All in One SEO Pro v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# SMURF-Therapeutics, Inc.

## Sitemaps

- [XML Sitemap](https://smurftherapeutics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation: Molecular Cell](https://smurftherapeutics.com/1-smurf2-predisposes-cancer-cell-toward-ferroptosis/)
- [The appointment of leadership announcement.](https://smurftherapeutics.com/the-appointment-of-leadership-announcement/)

## Pages

- [Home](https://smurftherapeutics.com/) - SMURF-Therapeutics, Inc. Treatments forcancer, anemia,and wound healing Targeting achilles heal of cancer growth. Improving anemia and wound healing. SMURF-Therapeutics, Inc. is developing small molecule therapeutics to activate or block Smurf2 for cancer, anemia and wound healing.
- [Technology](https://smurftherapeutics.com/technology/) - TECHNOLOGY TECHNOLOGY SMURF-Therapeutics, Inc. Smurf2 was discovered in the EL-DEIRY LAB at Brown University as a cellular protein that binds and degrades HIF1alpha (and HIF2alpha) in cancer cells treated with CDK4/6 inhibitor. Thus, drugs that boost Smurf2 levels in cancer cells and its binding to HIF proteins will have anti-cancer efficacy since HIF promotes tumor
- [Scientific Advisory Board](https://smurftherapeutics.com/scientific-advisory-board/) - Scientific Advisory Board Scientific Advisory Board J. Alan Diehl, PhD Chair, Department of Biochemistry Leonard and Jean Skeggs Endowed Professor, Deputy Director and COO, Case Comprehensive Cancer Center Case Western Reserve University. Dr. Diehl received formal training in Biochemistry as an undergraduate and graduate student where he investigated the regulation of oncogenic retroviruses. Dr. Diehl
- [Management](https://smurftherapeutics.com/management/) - Management and Team Management and Team SMURF-Therapeutics, Inc. SMURF-Therapeutics, Inc. is developing small molecule therapeutics to activate or block Smurf2 for cancer, anemia and wound healing. The company was founded by Wafik El-Deiry, MD, PhD, FACP in 2021 to develop small molecule compounds targeting hypoxia responses based on numerous academic research papers and reviews published
- [FOR-INVESTORS](https://smurftherapeutics.com/for-investors/) - FOR-INVESTORS FOR-INVESTORS Investor Presentations 15th January 2024
- [News archives](https://smurftherapeutics.com/news-archives/) - news archives news archives SMURF-Therapeutics NEWS ARCHIVES Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease | NEJMNov252021Time: 12:00 am - 12:00 am Read More Smurf2 Regulation of HIF-1α in Cancer CellsSep292021Time: 12:00 am - 12:00 am Watch Now Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase | OncotargetSep282021Time: 12:00 am - 12:00
- [News-media](https://smurftherapeutics.com/news-media/) - press releases press releases SMURF-Therapeutics, Inc. DEC 21st, 2023 Poster Presentation at Annual AACR DEC 21st, 2023 Publication of Smurf's Interaction with HIF PRESS RELEASES Dr. Emile Youssef appointed Chief Medical Officer at SMURF-Therapeutics, Inc.Jan292024Time: 12:00 amDownload PDF SMURF-Therapeutics, Inc. Announces Six New Appointments to Scientific Advisory BoardDec12023Time: 12:00 am - 12:00 amDownload PDF EVENTS
- [Resources](https://smurftherapeutics.com/resources/) - RESOURCES RESOURCES SMURF-Therapeutics, Inc. Cancer Patient Advocacy Groups: Leukemia & Lymphoma Society Cancer Support Community Susan G. Komen Colorectal Cancer Alliance Pancreatic Cancer Action Network Stupid Cancer Cancer Care Cancer Research and Guidelines: National Comprehensive Cancer Network The Cancer Genome Atlas National Cancer Institute PubMed Medical Resources for Healthcare Professionals: UpToDate American Cancer Society American
- [Pipeline](https://smurftherapeutics.com/pipeline/) - PIPELINE PIPELINE SMURF-Therapeutics, Inc. STAGES OF DEVELOPMENT Drugs or Combinations Indication Discovery Lead IC & PoC Lead Optimization IND-enabling Studies Clinical Trials SMURF-101 Anemia Combination Therapies SMURF-201 Advanced Solid Tumors Combination Therapies SMURF-301 (miR-targeting) Breast Cancer STAGES OF DEVELOPMENT Drugs or Combinations Indication Discovery Lead IC & PoC Lead Optimization IND-enabling Studies Clinical Trials SMURF-101
- [Contact Us](https://smurftherapeutics.com/contact-us/) - CONTACT US CONTACT US Get in Touch with Us Email: info@smurftherapeutics.com Address: Providence, Rhode Island
- [Expertise](https://smurftherapeutics.com/expertise/) - EXPERTISE EXPERTISE SMURF-Therapeutics, Inc. Anemia A hematological disorder of paramount clinical significance, is characterized by a quantitative deficiency in the circulating red blood cell mass or a qualitative impairment in hemoglobin content, leading to a diminished oxygen-carrying capacity of the blood. This multifaceted pathology stems from a myriad of etiological factors, encompassing nutritional deficiencies, chronic
- [Comming soon](https://smurftherapeutics.com/comming-soon/) - Be ready, we are launching soon. Coming Soon

## Landing Pages

- [Elementor Landing Page #332](https://smurftherapeutics.com/elementor-landing-page-332/) - Add Your Heading Text Here Add Your Heading Text Here Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

## Layouts

- [Footer Default (Education)](https://smurftherapeutics.com/layouts/footer-default-education/) - Pages Home Management and Team Scientific Advisory-Board Expertise Technology Pipeline Resources News and Media Contact Us Our Expertise AnemiaCancerFatigueMetastasesWell-beingWound healing SMURF-Therapeutics, Inc. Providence, Rhode Island info@smurftherapeutics.com Contact Us Investors and partners can contact us. © {{Y}} SMURF-Therapeutics, Inc. All Rights Reserved. Privacy Policy | Terms and Conditions
- [Header Simple Fullwidth (Education)](https://smurftherapeutics.com/layouts/header-simple-fullwidth-education/) - SMURF-Therapeutics HomeAbout Us Management and TeamScientific Advisory BoardExpertise TechnologyPipelineResourcesNews and Media Press ReleasesEvents & PresentationsIn the newsNews archives Contact UsFOR INVESTORS
- [Header Main (Education)](https://smurftherapeutics.com/layouts/header-main-education/) - Mon - Fri 8:00 - 18:00 / Sunday 8:00 - 14:00 1-800-458-56987 47 Bakery Street, London, UK HomeAbout Us Management and TeamScientific Advisory BoardExpertise TechnologyPipelineResourcesNews and Media Press ReleasesEvents & PresentationsIn the newsNews archives Contact UsFOR INVESTORS Header Main (Education)
- [MailChimp Popup](https://smurftherapeutics.com/layouts/mailchimp-popup/) - Subscribe to the updates! [mc4wp_form id="461" element_id="style-11"]
- [Events Header (Education)](https://smurftherapeutics.com/layouts/events-header-education/) - Mon - Fri 8:00 - 18:00 / Sunday 8:00 - 14:00 1-800-458-56987 47 Bakery Street, London, UK HomeAbout Us Management and TeamScientific Advisory BoardExpertise TechnologyPipelineResourcesNews and Media Press ReleasesEvents & PresentationsIn the newsNews archives Contact UsFOR INVESTORS
- [Video popup](https://smurftherapeutics.com/layouts/video-popup/)
- [top-header](https://smurftherapeutics.com/layouts/top-heaher/) - Lorem Ipsum Dolor Sit Amet HomeAbout Us Management and TeamScientific Advisory BoardExpertise TechnologyPipelineResourcesNews and Media Press ReleasesEvents & PresentationsIn the newsNews archives Contact UsFOR INVESTORS

## Events

- [SMURF-Therapeutics, Inc. Announces Six New Appointments to Scientific Advisory Board](https://smurftherapeutics.com/event/smurf-therapeutics-inc-announces-six-new-appointments-to-scientific-advisory-board/)
- [Dr. Emile Youssef appointed Chief Medical Officer at SMURF-Therapeutics, Inc.](https://smurftherapeutics.com/event/dr-emile-youssef-appointed-chief-medical-officer/)
- [Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance.](https://smurftherapeutics.com/event/novel-cancer-treatment-paradigm-targeting-hypoxia-induced-factor-in-conjunction-with-current-therapies-to-overcome-resistance/)
- [SMURF-2 data in 2023 AACR Poster Presentation](https://smurftherapeutics.com/event/smurf-2-data-in-2023-aacr-poster-presentation/)
- [SMURF2 predisposes cancer cell toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation: Molecular Cell](https://smurftherapeutics.com/event/smurf2-predisposes-cancer-cell-toward-ferroptosis-in-gpx4-independent-manners-by-promoting-gstp1-degradation-molecular-cell/)
- [FDA approves belzutifan for cancers associated with von Hippel-Lindau disease | FDA](https://smurftherapeutics.com/event/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease-fda/) - Read More
- [Identification of Smurf2 as a HIF-1α degrading E3 ubiquitin ligase | Oncotarget](https://smurftherapeutics.com/event/identification-of-smurf2-as-a-hif-1α-degrading-e3-ubiquitin-ligase-oncotarget/) - Read More
- [Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease | NEJM](https://smurftherapeutics.com/event/belzutifan-for-renal-cell-carcinoma-in-von-hippel-lindau-disease-nejm/) - Read More
- [Dr. Wafik El-Deiry comments on the future of cancer treatment](https://smurftherapeutics.com/event/dr-wafik-el-deiry-comments-on-the-future-of-cancer-treatment/) - Watch Now
- [Smurf2 Regulation of HIF-1α in Cancer Cells](https://smurftherapeutics.com/event/smurf2-regulation-of-hif-1α-in-cancer-cells/) - Watch Now

## Event categories

- [NEWS ARCHIVES](https://smurftherapeutics.com/event_cat/news-archives/)
- [PRESS RELEASES](https://smurftherapeutics.com/event_cat/press-releases/)
- [EVENTS & PRESENTATIONS](https://smurftherapeutics.com/event_cat/events-presentations/)
- [IN THE NEWS](https://smurftherapeutics.com/event_cat/in-the-news/)